Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset

  • Cho, Byoung Chul; 
  • Hayashi, Hidetoshi; 
  • Lee, Se-Hoon; 
  • Danchaivijitr, Pongwut; 
  • Cheng, Ying; 
  • 외 20명
Citations

WEB OF SCIENCE

7
Citations

SCOPUS

8

초록

Introduction: The incidence of epidermal growth factor receptor (EGFR) mutations is higher among Asian patients with advanced non-small cell lung cancer than the general advanced non-small cell lung cancer population. We evaluated the efficacy and safety of amivantamab in combination with lazertinib versus osimertinib in Asian participants from the phase 3 MARIPOSA study who had treatment-na & iuml;ve advanced non-small cell lung cancer with common EGFR mutations. Methods: Participants were randomized 2:2:1 to receive amivantamab-lazertinib, osimertinib alone, or lazertinib alone. The primary endpoint was progression-free survival based on blinded independent central review per RECIST v1.1. Secondary endpoints included overall survival, objective response rate, duration of response, and safety. Exploratory endpoints included extracranial progression-free survival and post-progression outcomes. Results: Of 1074 randomized participants, 629 were Asian, with 250 and 251 randomized to the amivantamablazertinib and osimertinib arms, respectively. Among Asian participants, at a median follow-up of 22.5 months, amivantamab-lazertinib showed a 35 % reduction in the risk of disease progression or death versus osimertinib (hazard ratio, 0.65; P < 0.001). Consistent with the overall population, median progression-free survival was 27.5 and 18.3 months in the amivantamab-lazertinib and osimertinib arms, respectively. The objective response rate was 88 % for amivantamab-lazertinib versus 85 % for osimertinib. The median duration of response among confirmed responders improved by 8.6 months for amivantamab-lazertinib versus osimertinib. Favorable trends were also seen for overall survival, extracranial progression-free survival, and post-progression outcomes for amivantamab-lazertinib over osimertinib. Adverse events in Asian participants were similar to those in the overall population. Conclusions: Amivantamab-lazertinib demonstrated superior progression-free survival versus osimertinib in Asian participants, with a tolerable safety profile. These results were consistent with those in the overall population.

키워드

Asian patient; Amivantamab; EGFR TKI; EGFR-mutated NSCLC
제목
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset
저자
Cho, Byoung Chul; Hayashi, Hidetoshi; Lee, Se-Hoon; Danchaivijitr, Pongwut; Cheng, Ying; Liu, Baogang; Lee, Jong-Seok; Alip, Adlinda; Xiong, Hailin; How, Soon Hin; Chang, Gee-Chen; Yang, James Chih-Hsin; Yoshioka, Hiroshige; Sendur, Mehmet Ali Nahit; Prabhash, Kumar; Azuma, Koichi; Lee, Yun-Gyoo; Lin, Chien-Chung; Matsumoto, Shingo; Sunpaweravong, Patrapim; Xia, Yichuan; Martinez, Melissa; Bauml, Joshua M.; Sethi, Seema; Lu, Shun
DOI
10.1016/j.lungcan.2025.108496
발행일
2025-06
유형
Article
저널명
Lung Cancer
권
204